CHI Immunogenicity Summit 8 October 2020 Presentation
Recently, regulatory agencies have lowered sensitivity requirements for anti-drug antibody (ADA) bioassays. Reaching lower sensitivity levels while maintaining drug tolerance may necessitate lengthy acid dissociation pre-treatment steps, affecting assay quality. We present miniaturized, microfluidic ADA immunoassays with an automated acid dissociation step that demonstrate high sensitivity, high-quality, and drug-tolerant assays.
John Chappell, BSc, CChem, CSci, FRSC
Application & Service Director
EMEA and Asia Pacific
Gyros Protein Technologies
If you have problems to view the webinar please contact firstname.lastname@example.org